Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to compare the percent change in LDL cholesterol induced by ezetimibe or simvastatin monotherapy and by co-administration of both agents in Black, White and Hispanic men. Ezetimibe is a drug that blocks sterol absorption and simvastatin blocks hepatic cholesterol biosynthesis. The hypothesis to be tested is that Blacks are likely to be more responsive to LDL lowering by ezetimibe than statins because Blacks have a low production of cholesterol.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Black, white and hispanic males between the ages of 20 to 70 years
In good general health
Having a body mass index (BMI) between 20 and 35 kg/m2
Plasma LDL-C concentrations greater than or equal to 130 mg/dl but less than or equal to 175 mg/dL
TG (triglyceride) levels less than or equal to 250 mg/dL.
Any condition that would be likely to render the individual unable to complete the study
Hypersensitivity to HMG-CoA reductase inhibitors
Poor mental function, drug or substance abuse, or unstable psychiatric illnesses that may interfere with optimal participation in the study
Treatment with another investigational drug within 30 days prior to Visit 1
Alcohol consumption >14 drinks per week
Phytosterol/phytostanol-containing products including margarines within 2 weeks
History of CHD, peripheral vascular disease, cerebrovascular disease, CHF, or uncontrolled arrhythmias
Creatinine >1.5 mg/dL, nephrotic syndrome, or other renal disease
Fasting plasma glucose (FPG) >126 mg/dL or history of diabetes
Uncontrolled hypertension (systolic BP >160 mm Hg and/or diastolic BP >100 mm Hg)
Known active liver diseases or elevated serum transaminases (ALT and AST >1.5 times the upper limit of normal)
Digestive disorders or any abdominal surgery within the past 6 months
Cancer within the past 5 years (except for skin cancer)
HIV, HBV, or HCV positive
Lipid-lowering agents: bile-acid binding resins, HMG-CoA reductase inhibitors, ezetimibe, niacin (>200 mg/day), cholestin, fish oil, and fibrates, or cholesterol absorption inhibitors (e.g., neomycin) taken within 8 weeks prior to Visit 1
Medications that are potent inhibitors of CYP3A4 (cyclosporine, systemic itraconazole or ketoconazole, erythromycin or clarithromycin, nefazodone, verapamil, amiodarone, and protease inhibitors)
Anti-obesity medications: orlistat or sibutramine taken within 8 weeks prior to Visit 1